Table 1. Examples of treatment durations and delays in random cytoprotective clinical trials.
Treatment duration is largely ignored in cytoprotective strategies [46–48], We argue that both short treatment delays and prolonged treatment durations may be required to maximize sustained therapeutic efficacy after AIS as this study concludes for PNU120596, a prototypical PAM of a7 nAChRs.
| Treatment Durations (from <24 h to 8 weeks) and Delavs In Random Cvtoorotective Clinical Trials | ||||
|---|---|---|---|---|
| <24 h | 48–72 h | 5–14 days | 4 weeks | 6–8 weeks |
| Drug/Delay to Treatment, h |
Drug/Delay to Treatment, h |
Drug/Delay to Treatment, h |
Drug/Delay to Treatment, h |
Drug/Delay to Treatment, h |
| Selfotel/6[87] Destrorphan/48[88] Aptiganel/6[89] Clomethiazole/12[90] UK-279,276/6[91] YM872/6 Nalmefene/6[92] Magnesium Sulfate/2 [93] Rhapsody/12[94] |
AR-R15896AR/12[95] NXY-059/24[50,96] GV150526/12[97,98] ZK200775/24[99] Tirilazad/6[100] IL-1 ra/6 [101] Sipatrigine/12[102] BMS-204352/6 Repinotan/4.5[103] Diazepam/12[104] DCLHB/18[105] |
Nimodipine/6-48[106] Enlimomab/6-24 [107,108] Lubeluzole/8[109] Ebselen/24[110] ONO-2506/6 Edaravone/24[111] |
Nimodipine/24–48 [112,113] Cerebrolysin/12–72 [114,115] |
Citicholine/6–24[116]* Piracetam/7[117]* |